Pay in 4 interest-free payments of $5.46 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
According to a study funded by Eli Lilly and published in the New England Journal of Medicine, people taking Zepbound lost nearly 50% more weight than those using rival Wegovy
A blood test is the only way to confirm it
These drugs were originally used to treat type 2 diabetes, but have become popular weight-loss tools over the past few years
This multi-dimensional therapeutic potential is reshaping the positioning of GLP-1 drugs as comprehensive metabolic treatments rather than just glucose-lowering agents For instance, Novo Nordisks semaglutide is now marketed as Wegovy specifically for chronic weight management, while Eli Lillys tirzepatide has received FDA approval under the brand name Zepbound for obesity treatment, independent of diabetic status
